

## A full case vs a single sentence

Fair Value EUR67 (+6%)

BUY-Top Picks

Bloomberg	IPN FP
Reuters	IPN.PA
12-month High / Low (EUR)	63.6 / 47.1
Market Cap (EUR)	5,264
Ev (BG Estimates) (EUR)	5,352
Avg. 6m daily volume (000)	75.50
3y EPS CAGR	13.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	8.3%	20.9%	21.3%	3.6%
Healthcare	-0.6%	-4.9%	0.6%	-9.5%
DJ Stoxx 600	-1.0%	4.5%	3.1%	-6.5%

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	1,444	1,566	1,714	1,866
% change		8.5%	9.4%	8.9%
EBITDA	366	407	462	544
EBIT	322.5	340.9	390.0	466.3
% change		5.7%	14.4%	19.5%
Net income	228.0	237.3	278.0	335.6
% change		4.1%	17.2%	20.7%

	2015	2016e	2017e	2018e
Operating margin	22.3	21.8	22.8	25.0
Net margin	12.5	14.0	14.1	15.9
ROE	15.5	16.9	16.7	17.8
ROCE	22.6	17.6	19.6	22.8
Gearing	-8.3	6.4	-0.2	-9.2

(€)	2015	2016e	2017e	2018e
EPS	2.78	2.89	3.39	4.09
% change	-	4.1%	17.2%	20.7%
P/E	22.7x	21.8x	18.6x	15.4x
FCF yield (%)	3.4%	3.7%	4.5%	5.5%
Dividends (€)	0.85	0.85	1.10	1.20
Div yield (%)	1.3%	1.3%	1.7%	1.9%
EV/Sales	3.6x	3.4x	3.1x	2.7x
EV/EBITDA	14.1x	13.2x	11.4x	9.4x
EV/EBIT	16.0x	15.7x	13.5x	10.9x

At ESMO principal investigator presented quite convincing phase II data for cabozantinib in 1L RCC that could be the base of a supplement filing ... despite a more balanced view from discussant.

## ANALYSIS

- What we are doing here is the summarized feedback from the third day at ESMO since CABOSUN phase II data were in highlight at the Presidential session.
- CABOSUN recruited 150 patients with clear-cell RCC naïve to therapy and having a poor or intermediate risk i.e. having the poorer prognosis (in 2L they will have between 5.4 and 16.6 months median survival rate), including 37% with bone metastases. This population represents between 70 and 75% of the overall RCC population.
- The primary endpoint was median PFS and it was expanded from 5.6 to 8.2 months (HR=0.69, p=0.012), with benefit across all subgroups, although it is fair to say that those with bone metastases benefited the most. The difference in ORR was also outstanding at 46% vs 18% (when assessed by investigator). Dose reductions occurred in 58% and 49% respectively in the cabo arm and the sunitinib arm and grade 3-4 side effects appeared very comparable across the two arms (65% vs 68%) and grade 5 AEs unfrequent (5% vs 4%). So these are very strong and consistent data in a setting where nothing has emerged since a long time.
- Everything was good until the last part of the presenter's speech when he stated that, based on the absence of median OS benefit (HR=0.80 with 30.3 months vs 21.8 but p=NS), he would not be comfortable prescribing the drug in 1L until confirmatory data from a phase III trial. This has come as a very unexpected comment from one of the most respected specialists in Europe. Exactly at that time, Exelixis's share price collapsed in the US.
- Asked similarly about what they would do, three US specialists invited by Ipsen and Exelixis went against this conclusion. They showed that sunitinib very much did as expected in this trial and like in previous ones and despite a limited follow-up, OS benefit is likely to be confirmed later. In any case, with a clear benefit on mPFS and ORR, cabozantinib proves superior to sunitinib and time will tell about nivolumab and others in this setting. In PC trials, it has been showed that cabozantinib might well prepare the milieu or make the environment permissive for a better effect of an IO drug. So cabo first makes a lot of sense, even though safety can be called into question. But patients might prefer an oral drug. Lastly, some preliminary phase I data, mostly in bladder cancers, showed interesting efficacy and safety data in heavily pre-treated patients that are reassuring for the safety of the combination and convinced Exelixis to start a phase II trial in bladder cancer. Cabo+Nivo vs Cabo then Nivo looks like an interesting phase III to perform.
- So, in the end, our belief is that cabozantinib, whatever its precise setting, is here to play a key role in RCC. Because of its mode of action that not only involves VEGFR pathway but also MET and AXL, it is now the TKI of choice and it is a bit too early to say how IO will navigate around. Moreover, 5-10% of patients that have immune diseases are not eligible to IO and those with bone mets are also clear candidates for cabo. So, the size of the market opportunity remains to be carefully measured but CABOSUN data are clearly helpful to give cabozantinib a central place in RCC.

## VALUATION

- What can now happen with 1L RCC? Well, the optimism to be able to file on phase II data has clearly increased at Exelixis and Ipsen. The ability to file by the end of H1 2017 and to have a variation procedure in Europe making it possible to get an approval by year-end 2018 is real. This would be a major upside to our scenario and although the median duration of treatment based on mPFS might not be massively increased by getting in 1L, it is said that about 40% of patients are lost between 1L and 2L, thus reducing dramatically the target population.
- We will reassess our main assumptions at a later stage.

## NEXT CATALYSTS

- 26 October 2016: Third-quarter sales - [Click here to download document](#)




## Analyst :

Eric Le Berrigaud  
33(0) 1 56 68 75 33  
[eleberrigaud@bryangarnier.com](mailto:eleberrigaud@bryangarnier.com)

## Sector Team :

Mickaël Chane Du  
Hugo Solvet



# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 56.5%

NEUTRAL ratings 31.8%

SELL ratings 11.7%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Munich</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			<b>Geneva</b>
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..